Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin

NCT03889496 · Terminated

Last updated 2026-05-28

This clinical trial tests whether a special imaging scan can measure the amount of insulin-producing cells in people with diabetes by tracking a radioactive tracer.

Status Terminated Stopped early and will not restart.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) study

Participants 12 people

Who can join Ages 18+ · all sexes

Timeline Started 2015-11 · est. completion 2021-06

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT03889496 ↗

Description as written by the study sponsor.

The main goal is to study the correlation of pancreatic uptake of In-111-DTPA-exendin-4 (measured by ex vivo counting) with the beta cell mass determined in the pancreatic specimens obtained after surgery.

Treatments tested

indium-111-exendin SPECT/CT Radiation

SPECT/CT imaging after injection with In-111-DTPA-exendin-4

Main thing measured	Correlation between the tracer uptake (counts) and beta cell mass (mg)
Sponsor	Radboud University Medical Center
Conditions studied	Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03889496 ↗